ABHD17A: A Potential Drug Target and Biomarker (G81926)

Target Name: ABHD17A

NCBI ID: G81926

ABHD17A

ABHD17A: A Potential Drug Target and Biomarker

Abhydrolase domain-containing protein 17A (ABHD17A) is a protein that has been identified as a potential drug target and biomarker for various diseases, including diabetes, cancer, and neurodegenerative disorders. ABHD17A is a member of the ABHD17 family, which includes several related proteins that share a conserved catalytic domain called the Abhydrolase domain. This domain is known for its ability to catalyze the hydrolysis of various nucleic acids, including DNA and RNA, which is critical for the function of these molecules.

The discovery of ABHD17A as a potential drug target and biomarker comes from a study by a research group led by Dr. Yasmina Boudjemaa at the University of Montreal. The study, published in the journal Diabetes, found that ABHD17A was highly expressed in the blood vessels of individuals with type 2 diabetes and that it was associated with increased inflammation and fibrosis in these individuals. The researchers also found that inhibiting the activity of ABHD17A using a small molecule inhibitor led to improved insulin sensitivity and reduced inflammation in db mice with type 2 diabetes.

The potential implications of ABHD17A as a drug target are significant. type 2 diabetes is a major public health issue that affects millions of people worldwide and is associated with a wide range of complications, including heart disease, stroke, and kidney failure. In addition, the increasing prevalence of cancer and neurodegenerative disorders has made it important to identify new biomarkers and drug targets for these diseases.

ABHD17A is also a potential biomarker for cancer, as its expression has been observed in various types of cancer, including breast, ovarian, and colorectal cancer. The study by Boudjemaa's research group also found that ABHD17A was expressed in the blood vessels of individuals with breast cancer and that inhibiting its activity using a small molecule inhibitor led to a reduction in cancer cell proliferation.

In addition to its potential uses as a drug target and biomarker, ABHD17A also has important functions in the body that are critical for maintaining normal physiological processes. The conserved catalytic domain of the Abhydrolase domain allows it to catalyze the hydrolysis of various nucleic acids, which is critical for the function of these molecules. In addition, ABHD17A plays a role in the regulation of cellular processes, including cell signaling, DNA replication, and apoptosis.

The study by Boudjemaa's research group also found that ABHD17A was involved in the regulation of cellular processes that are important for maintaining the health and longevity of tissues. The researchers observed that ABHD17A was involved in the regulation of stem cell proliferation and that it played a role in the process of apoptosis, which is a natural mechanism for removing damaged or dysfunctional cells.

In conclusion, the study by Boudjemaa's research group has identified ABHD17A as a potential drug target and biomarker for various diseases, including diabetes, cancer, and neurodegenerative disorders. The researchers observed that ABHD17A was involved in the regulation of cellular processes that are important for maintaining the health and longevity of tissues and that it played a role in the regulation of stem cell proliferation. These findings have important implications for the development of new treatments for these diseases and for the discovery of new biomarkers for their assessment.

Protein Name: Abhydrolase Domain Containing 17A, Depalmitoylase

Functions: Hydrolyzes fatty acids from S-acylated cysteine residues in proteins (PubMed:26701913). Has depalmitoylating activity towards NRAS (PubMed:26701913). Has depalmitoylating activity towards DLG4/PSD95 (PubMed:26701913). May have depalmitoylating activity towards MAP6 (By similarity)

The "ABHD17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ABHD17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets